Unnamed: 0,title,date,stock,sentiment
662255.0,"Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.",2020-06-08 11:41:00-04:00,IMMU,positive
662256.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,IMMU,positive
662257.0,"The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer",2020-05-28 08:24:00-04:00,IMMU,neutral
662258.0,Immunomedics Announces Its CEO And President Will Step Down,2020-05-27 16:01:00-04:00,IMMU,neutral
662259.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,IMMU,positive
662260.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,IMMU,neutral
662261.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,IMMU,neutral
662262.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,IMMU,neutral
662263.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,IMMU,positive
662264.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,IMMU,neutral
662265.0,Stocks That Hit 52-Week Highs On Friday,2020-05-15 10:33:00-04:00,IMMU,neutral
662266.0,Immunomedics Will Present New Trodelvy Data In Non-Breast Cancer Indications At ASCO,2020-05-13 17:28:00-04:00,IMMU,negative
662267.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,IMMU,neutral
662268.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,IMMU,negative
662269.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,IMMU,neutral
662270.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,IMMU,neutral
662271.0,"H.C. Wainwright Maintains Buy on Immunomedics, Lowers Price Target to $54",2020-05-07 10:38:00-04:00,IMMU,negative
662272.0,"Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to $32",2020-05-07 08:36:00-04:00,IMMU,neutral
662273.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,IMMU,negative
662274.0,Immunomedics Q3 EPS $(0.440) Beats $(0.450) Estimate,2020-05-06 16:02:00-04:00,IMMU,neutral
662275.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,IMMU,neutral
662276.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,IMMU,positive
662277.0,Why Immunomedics Is Trading Higher Today,2020-05-05 12:00:00-04:00,IMMU,neutral
662278.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,IMMU,neutral
662279.0,"Benzinga's Top Upgrades, Downgrades For May 5, 2020",2020-05-05 09:35:00-04:00,IMMU,positive
662280.0,Immunomedics shares are trading higher after Barclays initiated coverage on the company's stock with an Overweight rating and $40 price target.,2020-05-05 08:25:00-04:00,IMMU,negative
662281.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,IMMU,positive
662282.0,"Barclays Initiates Coverage On Immunomedics with Overweight Rating, Announces Price Target to $40",2020-05-05 05:39:00-04:00,IMMU,negative
662283.0,Immunomedics Reports Commercial Availability Of TRODELVY In US,2020-05-04 08:09:00-04:00,IMMU,neutral
662284.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,IMMU,neutral
662285.0,"Notable Insider Buys This Past Week: Immunomedics, Simply Good Foods And More",2020-05-02 17:56:00-04:00,IMMU,positive
662286.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,IMMU,positive
662287.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-29 10:16:00-04:00,IMMU,neutral
662288.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,IMMU,positive
662289.0,Immunomedics shares are trading lower after the company announced a proposed public offering of $350 million worth of its common stock.,2020-04-28 07:28:00-04:00,IMMU,positive
662290.0,13 Stocks Moving In Monday's After-Hours Session,2020-04-27 17:09:00-04:00,IMMU,neutral
662291.0,Immunomedics shares are trading lower after the company announced a proposed public offering of $350 million worth of its common stock.,2020-04-27 16:18:00-04:00,IMMU,positive
662292.0,Immunomedics Announces A Proposed Public Offering Of $350 Million Worth Of Its Common Stock. No Size Disclosed,2020-04-27 16:03:00-04:00,IMMU,negative
662293.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,IMMU,negative
662294.0,"Benzinga's Top Upgrades, Downgrades For April 24, 2020",2020-04-24 09:38:00-04:00,IMMU,positive
662295.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,IMMU,positive
662296.0,10 Biggest Price Target Changes For Friday,2020-04-24 08:12:00-04:00,IMMU,neutral
662297.0,"Goldman Sachs Upgrades Immunomedics to Neutral, Raises Price Target to $22",2020-04-24 06:31:00-04:00,IMMU,neutral
662298.0,76 Biggest Movers From Yesterday,2020-04-24 04:42:00-04:00,IMMU,neutral
662299.0,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop,2020-04-23 14:43:00-04:00,IMMU,positive
662300.0,P/E Ratio Insights for Immunomedics,2020-04-23 13:33:00-04:00,IMMU,neutral
662301.0,54 Stocks Moving In Thursday's Mid-Day Session,2020-04-23 12:24:00-04:00,IMMU,neutral
662302.0,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings,2020-04-23 12:20:00-04:00,IMMU,negative
662303.0,"Guggenheim Maintains Buy on Immunomedics, Raises Price Target to $39",2020-04-23 11:30:00-04:00,IMMU,neutral
662304.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,IMMU,neutral
662305.0,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views,2020-04-23 10:15:00-04:00,IMMU,neutral
662306.0,Immunomedics shares are trading higher after the FDA granted accelerated approval for the company's Trodelvy in previously-treated metastatic triple-negative breast cancer.,2020-04-23 08:37:00-04:00,IMMU,positive
662307.0,"Piper Sandler Maintains Overweight on Immunomedics, Raises Price Target to $40",2020-04-23 08:32:00-04:00,IMMU,negative
662308.0,10 Biggest Price Target Changes For Thursday,2020-04-23 08:29:00-04:00,IMMU,neutral
662309.0,"Wells Fargo Maintains Overweight on Immunomedics, Raises Price Target to $41",2020-04-23 08:15:00-04:00,IMMU,negative
662310.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,IMMU,negative
662311.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-23 07:31:00-04:00,IMMU,neutral
662312.0,38 Stocks Moving in Thursday's Pre-Market Session,2020-04-23 07:18:00-04:00,IMMU,neutral
662313.0,"H.C. Wainwright Maintains Buy on Immunomedics, Raises Price Target to $60",2020-04-23 07:11:00-04:00,IMMU,neutral
662314.0,FDA Grants Accelerated Approval for Immunomedics' Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer,2020-04-22 11:48:00-04:00,IMMU,negative
662315.0,Immunomedics Shares Unaffected As Traders Circulate Apr. 22-Dated FDA.gov Accessdata Site Showing Approval For Co.'s Trodelvy,2020-04-22 11:01:00-04:00,IMMU,positive
662316.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-22 10:20:00-04:00,IMMU,neutral
662317.0,"Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to $22",2020-04-15 10:08:00-04:00,IMMU,neutral
662318.0,Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further $2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.,2020-04-09 09:58:00-04:00,IMMU,positive
662319.0,"Immunomedics shares are trading higher after the company was granted FDA fast track designation for its Sactituzumab Goviteccan for the treatment of adult patients with locally advanced, and metastatic urothelial cancer.",2020-04-07 08:40:00-04:00,IMMU,negative
662320.0,"Immunomedics Reports FDA Granted Fast Track Designation For Sacituzumab Govitecan For Treatment Of Adult Patients With Locally Advanced, Metastatic Urothelial Cancer",2020-04-07 08:14:00-04:00,IMMU,negative
662321.0,"H.C. Wainwright Maintains Buy on Immunomedics, Raises Price Target to $34",2020-04-07 07:06:00-04:00,IMMU,neutral
662322.0,84 Biggest Movers From Yesterday,2020-04-07 05:47:00-04:00,IMMU,neutral
662323.0,Mid-Afternoon Market Update: Dow Surges Over 1200 Points; Millendo Therapeutics Shares Plummet,2020-04-06 14:30:00-04:00,IMMU,positive
662324.0,66 Stocks Moving In Monday's Mid-Day Session,2020-04-06 12:32:00-04:00,IMMU,neutral
662325.0,Mid-Day Market Update: Crude Oil Down Over 6%; Wayfair Shares Spike Higher,2020-04-06 12:13:00-04:00,IMMU,negative
662326.0,Mid-Morning Market Update: Markets Open Higher; Simply Good Foods Beats Q2 Estimates,2020-04-06 10:18:00-04:00,IMMU,positive
662327.0,Immunomedics Shares Roar Higher On 'Remarkable Results' For Drug Candidate,2020-04-06 10:14:00-04:00,IMMU,positive
662328.0,Immunomedics Shares Up 96% Following News Co. Stopped ASCENT Trial Early Due To Overwhelming Efficacy; Jefferies Sees Event As De-Risking Given SG Is Now Well Positioned To Get Accelerated Approval,2020-04-06 09:53:00-04:00,IMMU,positive
662329.0,Immunomedics shares are trading higher after the company said it would stop its Ascent Study due to compelling evidence of efficacy.,2020-04-06 09:10:00-04:00,IMMU,positive
662330.0,"Immunomedics Shares Resume Trade, Up 155%",2020-04-06 08:36:00-04:00,IMMU,positive
662331.0,Immunomedics Announces Ascent Study To Be Stopped For Compelling Evidence Of Efficacy,2020-04-06 08:09:00-04:00,IMMU,neutral
662332.0,"Immunomedics Inc  Appointed Harout Semerjian As President And Chief Executive Officer And As A Member Of Board, Effective April 16, 2020",2020-04-06 07:54:00-04:00,IMMU,positive
662333.0,Immunomedics Announces Harout Semerjian CEO,2020-04-06 07:51:00-04:00,IMMU,neutral
662334.0,74 Biggest Movers From Friday,2020-04-06 04:46:00-04:00,IMMU,neutral
662335.0,"Immunomedics Spokesperson Says Expecting To Address FDA Observations In Coming Weeks, Doesn't See Need For More Inspections",2020-04-03 15:29:00-04:00,IMMU,neutral
662336.0,40 Stocks Moving In Friday's Mid-Day Session,2020-04-03 12:39:00-04:00,IMMU,neutral
662337.0,"Immunomedics Could Face Second FDA Rejection For Breast Cancer Drug, Goldman Sachs Says In Double Downgrade",2020-04-03 10:34:00-04:00,IMMU,negative
662338.0,"Benzinga's Top Upgrades, Downgrades For April 3, 2020",2020-04-03 09:54:00-04:00,IMMU,positive
662339.0,Immunomedics shares are trading lower after Goldman Sachs downgraded the company's stock from Buy to Sell and announced a $5 price target.,2020-04-03 07:37:00-04:00,IMMU,neutral
662340.0,25 Stocks Moving in Friday's Pre-Market Session,2020-04-03 07:15:00-04:00,IMMU,neutral
662341.0,"Goldman Sachs Downgrades Immunomedics to Sell, Announces $5 Price Target",2020-04-03 06:31:00-04:00,IMMU,neutral
662342.0,"Immunomedics Shares Unaffected Following Circulation Of Dept. Of Health & Human Services Doc From FDA Related To Inspection Of Silver Spring, Maryland Facility",2020-04-02 11:46:00-04:00,IMMU,positive
662343.0,72 Biggest Movers From Yesterday,2020-04-02 04:23:00-04:00,IMMU,neutral
662344.0,"Cowen Says Spoke With Immunomedics Mgmt, Mgmt Remains Confirdent In Sacituzumab Approval; Firm Says Expects Drug To 'become standard of care in TNBC'",2020-04-01 13:16:00-04:00,IMMU,positive
662345.0,54 Stocks Moving In Wednesday's Mid-Day Session,2020-04-01 12:30:00-04:00,IMMU,neutral
662346.0,Mid-Day Market Update: ProPetro Slides After Q4 Results; InflaRx Shares Jump,2020-04-01 12:11:00-04:00,IMMU,positive
662347.0,Mid-Morning Market Update: Markets Open Lower; UniFirstTops Q2 Estimates,2020-04-01 10:26:00-04:00,IMMU,negative
662348.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,IMMU,negative
662349.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,IMMU,negative
662350.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,IMMU,negative
662351.0,"Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to $19",2020-03-03 08:14:00-05:00,IMMU,neutral
662352.0,"Immunomedics Q2 EPS $(0.5) Misses $(0.46) Estimate, Sales $300K Miss $530K Estimate",2020-02-27 16:00:00-05:00,IMMU,negative
662353.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,IMMU,positive
662354.0,"Shares of several healthcare companies are trading lower as markets fall amid the continued spread of the coronavirus, which has raised concerns of a global economic slowdown, impacting stocks across sectors.",2020-02-25 11:49:00-05:00,IMMU,neutral
662355.0,Immunomedics shares are trading higher in sympathy with the overall market on a rebound following Monday's steep selloff.,2020-02-25 09:10:00-05:00,IMMU,positive
662356.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,IMMU,neutral
662357.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,IMMU,positive
662358.0,5 Biggest Price Target Changes For Friday,2019-12-27 08:42:00-05:00,IMMU,neutral
662359.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,IMMU,neutral
662360.0,"HC Wainwright & Co. Maintains Buy on Immunomedics, Raises Price Target to $31",2019-12-27 07:08:00-05:00,IMMU,neutral
662361.0,60 Biggest Movers From Yesterday,2019-12-27 04:44:00-05:00,IMMU,neutral
662362.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-12-26 12:11:00-05:00,IMMU,neutral
662363.0,Immunomedics shares are trading higher after the company announced the FDA accepted for filing the company's BLA seeking accelerated approval of sacituzumab govitecan to treat metastatic triple-negative breast cancer.,2019-12-26 10:39:00-05:00,IMMU,positive
662364.0,Immunomedics Reports FDA Acceptance Of Filing Of Biologics License Application Resubmission For Sacrituzumab Govitecan To Treat Metastatic Triple-Negative Breast Cancer,2019-12-26 08:01:00-05:00,IMMU,positive
662365.0,"UPDATE: Bank Of America On Immunomedics Notes Co's ADC Sacituzumab Govitecan In Triple Negative Breast Cancer 'showed a 33% overall response rate (ORR) in third-line in ph 2 study, which we view positively' Has Potential To Disrupt Current Paradigm",2019-12-20 12:12:00-05:00,IMMU,negative
662366.0,"UPDATE: Bank Of America Initiates Immunomedics With Buy, $26 Target Notes Co's 'Novel ADC platform tackling cancers of high undermet need'",2019-12-20 12:11:00-05:00,IMMU,positive
662367.0,"Bank of America Initiates Coverage On Immunomedics with Buy Rating, Announces $26 Price Target",2019-12-20 12:04:00-05:00,IMMU,neutral
662368.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,IMMU,positive
662369.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-11 10:49:00-05:00,IMMU,neutral
662370.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,IMMU,negative
662371.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-10 14:27:00-05:00,IMMU,neutral
662372.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,IMMU,positive
662373.0,Immunomedics Announces The Closing Of The Public Offering Of Common Stock,2019-12-09 16:04:00-05:00,IMMU,neutral
662374.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,IMMU,neutral
662375.0,"Immunomedics shares are trading higher in sympathy with the overall market after the U.S. added 266,000 jobs in November, beating expectations and lowering the unemployment rate to 3.5%.",2019-12-06 10:05:00-05:00,IMMU,negative
662376.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,IMMU,neutral
662377.0,Mid-Afternoon Market Update: Dow Rises Over 200 Points; Barnes & Noble Education Shares Slide,2019-12-04 14:36:00-05:00,IMMU,positive
662378.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-12-04 12:02:00-05:00,IMMU,neutral
662379.0,Immunomedics shares are trading lower after the company announced a proposed offering of $250 million of common stock.,2019-12-04 09:09:00-05:00,IMMU,neutral
662380.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-12-04 07:24:00-05:00,IMMU,neutral
662381.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,IMMU,negative
662382.0,Immunomedics shares are trading lower after the company announced a proposed offering of $250 million of common stock.,2019-12-03 16:09:00-05:00,IMMU,neutral
662383.0,Immunomedics Announces Proposed Public Offering Of $250M Of Common Stock,2019-12-03 16:04:00-05:00,IMMU,neutral
662384.0,Immunomedics Resubmits Biologics License Application To FDA For Sacituzumab Govitecan,2019-12-03 08:01:00-05:00,IMMU,neutral
662385.0,Immunomedics Option Alert: Jan 17 $19 Calls Sweep (2) above Ask!: 1000 @ $1.775 vs 5155 OI; Ref=$18.87,2019-11-26 11:01:00-05:00,IMMU,positive
662386.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More",2019-11-24 16:19:00-05:00,IMMU,positive
662387.0,Immunomedics shares are trading lower. Not currently seeing any company-specific news.,2019-11-19 14:38:00-05:00,IMMU,neutral
662388.0,Immunomedics shares are trading higher in sympathy with the overall market on better-than-expected October jobs growth and optimism around the U.S.-China trade deal.,2019-11-01 13:48:00-04:00,IMMU,positive
662389.0,Immunomedics Q1 EPS $(0.49) Down From $(0.34) YoY,2019-10-30 16:00:00-04:00,IMMU,neutral
662390.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,IMMU,negative
662391.0,Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption,2019-10-23 16:27:00-04:00,IMMU,neutral
662392.0,54 Biggest Movers From Yesterday,2019-10-17 05:52:00-04:00,IMMU,neutral
662393.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-10-16 12:35:00-04:00,IMMU,neutral
662394.0,Immunomedics shares are trading higher despite no company-specific news. The could potentially be a rebound after the stock dropped approximately 13% over the past month.,2019-10-16 11:23:00-04:00,IMMU,positive
662395.0,"Notable Insider Buys In The Past Week: Immunomedics, Tenet Healthcare, Ulta Beauty",2019-10-06 17:27:00-04:00,IMMU,positive
662396.0,28 Stocks Moving In Thursday's Mid-Day Session,2019-10-03 12:45:00-04:00,IMMU,neutral
662397.0,Immunomedics shares are trading higher on continued momentum after the company announced a research collaboration with the US Department of Defense to develop a new therapeutic against campylobacter.ï»¿,2019-10-03 11:54:00-04:00,IMMU,positive
662398.0,Immunomedics shares are trading higher after the company announced a research collaboration with the US Department of Defense to develop a new therapeutic against campylobacter.,2019-10-02 11:57:00-04:00,IMMU,positive
662399.0,Immuron Announces Research Collaboration With US Department Of Defense To Develop And Clinically Evaluate New Therapeutic Against Campylobacter,2019-10-02 09:01:00-04:00,IMMU,positive
662400.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,IMMU,negative
662401.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,IMMU,neutral
662402.0,"Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More",2019-09-30 13:13:00-04:00,IMMU,positive
662403.0,31 Stocks Moving In Monday's Mid-Day Session,2019-09-30 13:13:00-04:00,IMMU,neutral
662404.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019",2019-09-30 12:05:00-04:00,IMMU,neutral
662405.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019",2019-09-30 11:31:00-04:00,IMMU,positive
662406.0,18 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-30 08:44:00-04:00,IMMU,neutral
662407.0,24 Stocks Moving in Monday's Pre-Market Session,2019-09-30 08:41:00-04:00,IMMU,neutral
662408.0,Immunomedics shares are trading lower after interim data from the company's phase 2 study of Sacituzumab Govitecan showed a 29% response rate.,2019-09-30 08:27:00-04:00,IMMU,neutral
662409.0,"Wells Fargo Maintains Market Perform on Immunomedics, Raises Price Target to $16",2019-09-30 08:06:00-04:00,IMMU,positive
662410.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,IMMU,neutral
662411.0,Immunomedics shares are trading lower despite no company-specific news. The stock has dropped approximately 16% in the past 5 days.,2019-09-26 11:32:00-04:00,IMMU,positive
662412.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,IMMU,negative
662413.0,"Immunomedics shares are trading lower, not seeing any company-specific news to justify price action.",2019-09-24 12:43:00-04:00,IMMU,neutral
662414.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,IMMU,neutral
662415.0,Immunomedics shares are trading higher. This could potentially be continued momentum as the stock has rallied 26% over the past 5 days.,2019-09-13 13:34:00-04:00,IMMU,positive
662416.0,Immunomedics shares are trading higher in sympathy with healthcare stocks. Not seeing any company-specific news to justify move.,2019-09-11 15:17:00-04:00,IMMU,positive
662417.0,80 Biggest Movers From Yesterday,2019-09-11 05:11:00-04:00,IMMU,neutral
662418.0,"CORRECTION: Jefferies Earlier Made Negative Comments On Data From Immunomedics Competitor, Daiichi; Initial headline incorrectly suggested the negative comments were on Immunomedics",2019-09-10 13:17:00-04:00,IMMU,negative
662419.0,"Immunomedics shares trading higher following data out of competitor in non-small cell lung cancer space, Daiichi. A Piper Jaffray analyst said while efficacy of Daiichi's candidate was impressive, there were some safety signals popping up.",2019-09-10 13:15:00-04:00,IMMU,positive
662420.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-09-10 12:19:00-04:00,IMMU,neutral
662421.0,Immunomedics Shares Higher; Jefferies Made Negative Comments On Competitor Data In Non-Small Cell Lung Cancer Space From Daiichi,2019-09-10 11:07:00-04:00,IMMU,negative
662422.0,Immunomedics Highlights Oral Presentation Of Sactiuzumab Govitecan In Metastatic Urothelial Cancer At ESMO,2019-09-04 07:45:00-04:00,IMMU,negative
662423.0,"Benzinga's Top Upgrades, Downgrades For August 20, 2019",2019-08-20 09:33:00-04:00,IMMU,positive
662424.0,"Cantor Fitzgerald Initiates Coverage On Immunomedics with Overweight Rating, Announces $28 Price Target",2019-08-20 06:38:00-04:00,IMMU,negative
662425.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,IMMU,neutral
662426.0,Immunomedics Q4 EPS $(0.4) Up From $(0.68) YoY,2019-08-07 16:01:00-04:00,IMMU,neutral
662427.0,"The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV",2019-07-10 07:17:00-04:00,IMMU,positive
662428.0,"Notable Insider Buys This Past Week: AbbVie, MGM and More",2019-06-30 10:09:00-04:00,IMMU,neutral
662429.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,IMMU,positive
662430.0,"Notable Insider Buys This Past Week: American Airlines, MGM and More",2019-06-09 16:28:00-04:00,IMMU,neutral
662431.0,"Immunomedics Shares Tick Higher, Now At Session High Up 4%, Following 2.4M Share Black Trade At $12.70/Share",2019-06-07 13:40:00-04:00,IMMU,positive
662432.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,IMMU,neutral
662433.0,"Immunomedics Q3 EPS $(0.46) Misses $(0.36) Estimate, Sales $500K Up From $482.226K YoY",2019-05-09 07:15:00-04:00,IMMU,negative
662434.0,42 Biggest Movers From Yesterday,2019-04-30 07:05:00-04:00,IMMU,neutral
662435.0,38 Stocks Moving In Monday's Mid-Day Session,2019-04-29 12:36:00-04:00,IMMU,neutral
662436.0,"Immunomedics shares are trading lower after the company announced the departure of their Chief Medical Officer, who is pursuing a career closer to his home in Pennsylvania.",2019-04-29 10:11:00-04:00,IMMU,neutral
662437.0,"Immunomedics to License Sacituzumab Govitecan in Asia to Everest Medicines, Immunomedics to Receive $65M Upfront",2019-04-29 07:42:00-04:00,IMMU,neutral
662438.0,Immunomedics Reports Promotion Deal In Which Co. Will Provide Detailing Services To J&J's Janssen For Erdafitinib In US,2019-04-08 09:02:00-04:00,IMMU,neutral
662439.0,"Immunomedics shares are trading lower after the company entered into a sales agreement with Cowen and Company to issue and sell up to $150,000,000 worth of the company's common stock from time to time during the term of the agreement.",2019-04-01 15:25:00-04:00,IMMU,positive
662440.0,30 Stocks Moving In Monday's Pre-Market Session,2019-03-25 08:11:00-04:00,IMMU,neutral
662441.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2019",2019-03-04 09:01:00-05:00,IMMU,positive
662442.0,"H.C. Wainwright Initiates Coverage On Immunomedics with Buy Rating, Announces $28 Price Target",2019-03-04 07:13:00-05:00,IMMU,neutral
662443.0,"Immunomedics shares have rebounded from pre-market weakness, now trading higher.",2019-02-26 13:20:00-05:00,IMMU,negative
662444.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,IMMU,positive
662445.0,"Immunomedics Reports 6-Month Period Ended Dec. 31, 2018 EPS $(0.84) vs $(0.88) In Same Period Last Year",2019-02-25 16:38:00-05:00,IMMU,neutral
662446.0,"Immunomedics Highlights Publication Of Updated Data From Phase 2 Study Of Sacituzumab Govitecan In Patients With Metastatic Triple-Negative Breast Cancer On NEJM.org; Showed Overall Response rate 33.3%, Median Duration Of Response 7.7 Months",2019-02-20 17:09:00-05:00,IMMU,negative
662447.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,IMMU,positive
662448.0,21 Stocks Moving In Friday's Pre-Market Session,2019-01-25 08:03:00-05:00,IMMU,neutral
662449.0,"Morgan Stanley Downgrades Immunomedics to Equal-Weight, Lowers Price Target to $17",2019-01-22 06:46:00-05:00,IMMU,negative
662450.0,52 Biggest Movers From Friday,2019-01-22 05:08:00-05:00,IMMU,neutral
662451.0,Mid-Afternoon Market Update: Dow Climbs Over 300 Points; Nautilus Shares Slide On Weak Guidance,2019-01-18 14:33:00-05:00,IMMU,negative
662452.0,Immunomedics Shares Crash As Breast Cancer Drug Fails To Obtain Regulatory Nod,2019-01-18 12:31:00-05:00,IMMU,negative
662453.0,36 Stocks Moving In Friday's Mid-Day Session,2019-01-18 12:30:00-05:00,IMMU,neutral
662454.0,Mid-Day Market Update: Crude Oil Up 2.8%; Tyme Technologies Shares Plummet,2019-01-18 12:29:00-05:00,IMMU,negative
662455.0,Mid-Morning Market Update: Markets Open Higher; Tesla Cuts 7% Of Workforce,2019-01-18 10:13:00-05:00,IMMU,negative
662456.0,Immunomedics shares are trading down after the company received a CRL from the FDA for its Sacituzumab Govitecan Biologics License Application.,2019-01-18 09:30:00-05:00,IMMU,positive
662457.0,UPDATE: Wells Fargo Downgrades Immunomedics 'following yesterday's (1/17) complete response letter (CRL) from FDA for the sacituzumab govitecan BLA In triple negative breast cancer',2019-01-18 09:24:00-05:00,IMMU,negative
662458.0,"Wells Fargo Downgrades Immunomedics to Market Perform, Lowers Price Target to $18",2019-01-18 07:58:00-05:00,IMMU,positive
662459.0,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",2019-01-18 07:49:00-05:00,IMMU,neutral
662460.0,Immunomedics Receives CRL From FDA for Sacituzumab Govitecan Biologics License Application,2019-01-18 03:32:00-05:00,IMMU,neutral
662461.0,UPDATE: Immunomedics Filing Shows Final Award Denied Goldenberg's Claim He Was Entitled To $1.5M Award,2019-01-16 17:22:00-05:00,IMMU,positive
662462.0,"Immunomedics 8-K Shows Co. Received Arbitrator's Findings Of Fact, Conclusions Of Law, Final Award In Matter With David Goldenberg",2019-01-16 17:21:00-05:00,IMMU,positive
662463.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-01-13 15:50:00-05:00,IMMU,neutral
662464.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2018-12-31 09:00:00-05:00,IMMU,neutral
662465.0,"Immunomedics 8-K Shows Co. Entered Deal With BSP Pharma To 'negotiate in good faith to execute, deliver a definitive agreement for the commercial supply by BSP to the Co. of the Co.'s sacituzumab govitecan'",2018-12-28 09:03:00-05:00,IMMU,positive
662466.0,54 Biggest Movers From Yesterday,2018-12-27 05:55:00-05:00,IMMU,neutral
662467.0,Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge,2018-12-26 14:33:00-05:00,IMMU,positive
662468.0,33 Stocks Moving In Wednesday's Mid-Day Session,2018-12-26 12:37:00-05:00,IMMU,neutral
662469.0,Immunomedics shares are trading higher after the company and Johnson Matthey announced the companies have expanded their long-term master supply agreement under which Johnson Matthey will continue to scale the manufacturing of Immunomedics' CL2A-SN-38.,2018-12-26 11:33:00-05:00,IMMU,positive
662470.0,Immunomedics And Johnson Matthey Announce Strategic Manufacturing Partnership,2018-12-26 08:03:00-05:00,IMMU,neutral
662471.0,60 Biggest Movers From Friday,2018-12-24 04:35:00-05:00,IMMU,neutral
662472.0,40 Stocks Moving In Friday's Mid-Day Session,2018-12-21 12:40:00-05:00,IMMU,neutral
662473.0,30 Stocks Moving In Friday's Pre-Market Session,2018-12-21 08:02:00-05:00,IMMU,neutral
662474.0,60 Biggest Movers From Yesterday,2018-12-21 05:11:00-05:00,IMMU,neutral
662475.0,46 Stocks Moving In Thursday's Mid-Day Session,2018-12-20 12:37:00-05:00,IMMU,neutral
662476.0,Immunomedics shares are trading lower following reports of a data integrity breach.,2018-12-20 11:11:00-05:00,IMMU,positive
662477.0,"Immunomedics Shares Down 23% On Report Of Data Integrity Breach; Hearing Morgan Stanley Has Defended Co./Stock, Suggesting Co. Mgmt. Has Said Issues Were Discovered In Late 2017, 2018",2018-12-20 11:10:00-05:00,IMMU,positive
662478.0,'FDA Hits Immunomedics for Data Integrity Breach' -FDA News Reported Earlier This Week,2018-12-20 10:11:00-05:00,IMMU,positive
662479.0,Hearing Of A Bearish Report From Favus Institutional Research On Immunomedics,2018-12-20 10:07:00-05:00,IMMU,neutral
662480.0,"Jim Cramer Weighs In On Exelon, Okta, Wrkco And More",2018-12-04 07:25:00-05:00,IMMU,neutral
662481.0,"13F From Omega Shows Liquidated Positions In Halcon, Humana, Int'l. Game Tech., Immunomedics, Insmed, Iqvia, KKR, Lennar",2018-11-14 10:38:00-05:00,IMMU,neutral
662482.0,Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer,2018-11-07 16:11:00-05:00,IMMU,negative
662483.0,"Immunomedics, Inc. Q1 EPS $(0.34) Misses $(0.28) Estimate",2018-11-07 16:09:00-05:00,IMMU,negative
662484.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,IMMU,negative
662485.0,"UPDATE: Morgan Stanley Earlier On New Overweight Rating For Immunomedics: Believes Approval Of IMMU-132 By Jan. 18, 2019 PDUFA Will Serve As A Robust Near-Term Catalyst",2018-11-05 15:50:00-05:00,IMMU,positive
662486.0,"Morgan Stanley Initiates Coverage On Immunomedics with Overweight Rating, Announces $38 Price Target",2018-11-05 09:17:00-05:00,IMMU,negative
662487.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,IMMU,neutral
662488.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,IMMU,negative
662489.0,"PiperJaffray Earlier Initiated Coverage On Immunomedics with Overweight Rating, Announced $33 Price Target",2018-10-19 12:14:00-04:00,IMMU,negative
662490.0,"Goldman Sachs Initiates Coverage On Immunomedics with Buy Rating, Announces $36 Price Target",2018-09-17 08:24:00-04:00,IMMU,neutral
662491.0,UPDATE: Immunomedics Is Obligated To Pay Samsung Each Year From 2020 To 2025 Greater Of Min. Product Purchase Commitment As Set Forth In PSA,2018-09-12 08:30:00-04:00,IMMU,positive
662492.0,"Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership, 
Partnership Involves Commercial-scale Production of hRS7, the Antibody Used in Immunomedics' Lead Antibody-Drug Conjugate, Sacituzumab Govitecan",2018-09-12 08:03:00-04:00,IMMU,neutral
662493.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,IMMU,positive
662494.0,Immunomedics 8-K Shows Michael Garone Resigned As CFO; Usama Malik Named Interim Replacement,2018-08-23 16:25:00-04:00,IMMU,negative
662495.0,"Immunomedics Q4 EPS $(0.68) Misses $(0.22) Estimate, Sales $400K Miss $4.27M Estimate",2018-08-23 16:00:00-04:00,IMMU,negative
662496.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,IMMU,negative
662497.0,"Earnings Scheduled For August 23, 2018",2018-08-23 04:08:00-04:00,IMMU,neutral
662498.0,"Immunomedics Announces Clinical and Preclinical Collaborations with Yale University, MemMemorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Research Center",2018-07-30 08:07:00-04:00,IMMU,negative
662499.0,Immunomedics Reports Clinical Partnership With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers,2018-07-23 08:08:00-04:00,IMMU,neutral
662500.0,Immunomedics to Collaborate with AstraZeneca to Evaluate the Combination of Imfinzi and Sacituzumab Govitecan,2018-07-23 08:07:00-04:00,IMMU,neutral
662501.0,"Immunomedics Reports FDA Accepted Biologics License Application For Filing, Grants Priority Review For Sacituzumab Govitecan For Treatment Of Metastatic Triple-negative Breast Cancer",2018-07-18 08:06:00-04:00,IMMU,negative
662502.0,Immunomedics Prices 11.5M Share Offering At $24/Share,2018-06-13 08:02:00-04:00,IMMU,positive
662503.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-06-12 12:29:00-04:00,IMMU,neutral
662504.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,IMMU,positive
662505.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-06-12 08:01:00-04:00,IMMU,neutral
662506.0,"8 Stocks To Watch For June 12, 2018",2018-06-12 04:25:00-04:00,IMMU,neutral
662507.0,7 Stocks Moving In Monday's After-Hours Session,2018-06-11 17:20:00-04:00,IMMU,neutral
662508.0,UPDATE: Immunomedics Reports Offering Of $275M In Common Stock,2018-06-11 16:16:00-04:00,IMMU,neutral
662509.0,"Immunomedics Filing Shows Registration For Mixed Securities Shelf Offering, No Amount Disclosed",2018-06-11 16:13:00-04:00,IMMU,neutral
662510.0,"Immunomedics Amended 13D Filing From Seattle Genetics Shows Reduced Stake From ~11.66M Shares To ~8.28M Shares, Or 4.9% Stake",2018-06-05 16:29:00-04:00,IMMU,positive
662511.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,IMMU,positive
662512.0,44 Biggest Movers From Yesterday,2018-06-05 05:27:00-04:00,IMMU,neutral
662513.0,5 Biotech Stocks Moving On ASCO Presentations,2018-06-04 13:18:00-04:00,IMMU,neutral
662514.0,35 Stocks Moving In Monday's Mid-Day Session,2018-06-04 12:32:00-04:00,IMMU,neutral
662515.0,Mid-Morning Market Update: Markets Open Higher; Palo Alto Networks Beats Q3 Estimates,2018-06-04 10:13:00-04:00,IMMU,neutral
662516.0,"Clovis Oncology, Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers",2018-06-03 20:56:00-04:00,IMMU,neutral
662517.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,IMMU,negative
662518.0,Immunomedics Announces Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer at #ASCO2018,2018-06-03 19:10:00-04:00,IMMU,negative
662519.0,UPDATE: Immunomedics Reports Plan To Initiate Phase 2 Pivotal TROPHY U-01 Study Of Sacituzumab Govitecan As Single Agent In Patients With Locally-Advanced Or Metastatic Urothelial Cancer Who Have Relapsed After Platinum-Based Regimen,2018-06-01 08:10:00-04:00,IMMU,negative
662520.0,Immunomedics Reports Pivotal Study Of Sacituzumab Govitecan In Patients With Locally-Advanced Or Metastatic Urothelial Cancer,2018-06-01 08:09:00-04:00,IMMU,negative
662521.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,IMMU,neutral
662522.0,Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The FDA,2018-05-21 08:04:00-04:00,IMMU,neutral
662523.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,IMMU,positive
662524.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,IMMU,neutral
662525.0,"Immunomedics Reports Sacituzumab Govitecan Generated Confirmed Overall Response Rate Of 31% In Heavily Pre-Treated ER+/HER2-mBC Patients, 6-Month Clinical Benefit Was 48%",2018-05-16 17:19:00-04:00,IMMU,positive
662526.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,IMMU,neutral
662527.0,"Immunomedics Q3 EPS $(0.21) Misses $(0.15) Estimate, Sales $500K Miss $4.27M Estimate",2018-05-09 16:00:00-04:00,IMMU,negative
662528.0,36 Biggest Movers From Yesterday,2018-05-01 05:02:00-04:00,IMMU,neutral
662529.0,36 Stocks Moving In Monday's Mid-Day Session,2018-04-30 13:16:00-04:00,IMMU,neutral
662530.0,Shares Of Immunomedics Quiet As Co. Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting,2018-04-25 12:17:00-04:00,IMMU,negative
662531.0,"For Now, Traders Endorse Biotech Rally",2018-03-28 11:43:00-04:00,IMMU,positive
662532.0,"Immunomedics Reports Q2 EPS $(0.02) vs $(0.12) Est., Sales $600K vs $400K In Prior Year Period",2018-02-08 16:29:00-05:00,IMMU,neutral
662533.0,"JP Morgan Healthcare Conference Concludes Today, Presenters Include: CymaBay, Orthofix, Analogic, Achaogen, Immunomedics, and Dynavax",2018-01-11 09:07:00-05:00,IMMU,positive
662534.0,Immunomedics Reports Deal With University Of Wisconsin Carbone Cancer Center To Expand IMMU-132 Into Prostate Cancer,2018-01-11 08:01:00-05:00,IMMU,negative
662535.0,"Immunomedics Earlier Announced $250M Royalty Funding And Stock Purchase Agreement With Royalty Pharma; Co. Has Sold Rights To Sacituzumab Govitecan To Royalty Pharma For $175M And Also Received $75M Equity Investment, Valuing Shares At $17.15/Share",2018-01-08 12:54:00-05:00,IMMU,positive
662536.0,Immunomedics Shares Halted News Pending,2018-01-08 08:28:00-05:00,IMMU,positive
662537.0,32 Biggest Movers From Yesterday,2017-12-08 05:05:00-05:00,IMMU,neutral
662538.0,"Immunomedics Option Alert: Jan, 2019 $12 Puts at the Bid: 2000 @ $4.1 vs 243 OI; Ref=$11.935",2017-12-07 15:09:00-05:00,IMMU,positive
662539.0,31 Stocks Moving In Thursday's Mid-Day Session,2017-12-07 12:24:00-05:00,IMMU,neutral
662540.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-12-07 08:02:00-05:00,IMMU,neutral
662541.0,42 Biggest Movers From Yesterday,2017-12-07 05:14:00-05:00,IMMU,neutral
662542.0,UPDATE: Immunomedics Reports IMMU-132's Updated Clinical Benefit Rate is at 6 Months = 45% (Locally Assessed),2017-12-06 12:12:00-05:00,IMMU,positive
662543.0,UPDATE: Immunomedics Announces Submission of Biologics License Application (BLA) for Accelerated Approval of Sacituzumab Govitecan as Third-Line Treatment for mTNBC Remains on Track for Q1 2018,2017-12-06 12:11:00-05:00,IMMU,positive
662544.0,"Immunomedics Announces IMMU-132 Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed), Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed)",2017-12-06 12:10:00-05:00,IMMU,neutral
662545.0,"Immunomedics Shares Resume Trading, Up ~20% At $10.88",2017-12-06 12:00:00-05:00,IMMU,positive
662546.0,Immunomedics Shares Halted On Circuit Breaker After Moving +11.4% In 10 Minutes,2017-12-06 11:54:00-05:00,IMMU,positive
662547.0,"IMMU Option Alert: Jan, 2019 $5 Puts Sweep (3) at the Bid: 500 @ $1.15 vs 525 OI; Ref=$9.1",2017-12-06 11:54:00-05:00,IMMU,positive
662548.0,32 Biggest Movers From Yesterday,2017-12-05 06:05:00-05:00,IMMU,neutral
662549.0,"Jim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics",2017-12-01 07:37:00-05:00,IMMU,neutral
662550.0,"Immunomedics Shares Up ~20% Over Last 2 Sessions; Several Execs/Insiders Filed Form 4's Showing Purchase Of 2.8M Shares, Including 1.325M Shares Via venBio Advisor; Stock Has Been Rangebound Between $10 And $12.50 Since Reporting Q1 Earnings On Nov. 9",2017-11-16 11:58:00-05:00,IMMU,positive
662551.0,"Immunomedics 10%+ Owner venBio Select Advisor LLC  Buys 1,325,000 @ Avg Price: $10.47 -Form4",2017-11-16 11:49:00-05:00,IMMU,neutral
662552.0,"Seeing Notable Block Trade In Immunomedics of 1.3M Shares At $10.20, Below $10.26 Bid",2017-11-14 13:45:00-05:00,IMMU,negative
662553.0,34 Biggest Movers From Yesterday,2017-11-14 05:52:00-05:00,IMMU,neutral
662554.0,44 Biggest Movers From Friday,2017-11-13 05:41:00-05:00,IMMU,neutral
662555.0,35 Stocks Moving In Friday's Mid-Day Session,2017-11-10 12:41:00-05:00,IMMU,neutral
662556.0,Mid-Day Market Update: Omeros Climbs After Strong Q3 Results; LightPath Technologies Shares Plunge,2017-11-10 12:00:00-05:00,IMMU,positive
662557.0,31 Stocks Moving In Friday's Pre-Market Session,2017-11-10 08:19:00-05:00,IMMU,neutral
662558.0,Immunomedics Names Michael Pehl President and CEO,2017-11-09 16:43:00-05:00,IMMU,neutral
662559.0,"Immunomedics Reports Q1 EPS $(0.97) vs ~$(0.17) In Same Qtr. Last Year, Sales $700K",2017-11-09 16:11:00-05:00,IMMU,neutral
662560.0,Watch These 10 Huge Put Purchases In Thursday Trade,2017-09-28 04:13:00-04:00,IMMU,positive
662561.0,Benzinga's Option Alert Recap From September 27,2017-09-27 16:13:00-04:00,IMMU,positive
662562.0,Immunomedics Option Alert: Jan 19 $10 Puts Sweep (4) at the Ask: 1000 @ $0.919 vs 96 OI; Ref=$12.77,2017-09-27 11:51:00-04:00,IMMU,positive
662563.0,Immunomedics Shares Fall ~$0.40-$0.50 Over Last Min. As Traders Circulate Negative Report From Mako Research,2017-09-20 09:31:00-04:00,IMMU,negative
662564.0,Mid-Afternoon Market Update: Dow Rises Over 50 Points; T2 Biosystems Shares Plummet,2017-09-15 14:31:00-04:00,IMMU,positive
662565.0,PfizerImmunomedics Gives Update on Interim Phase 2 IMMU-132 Data,2017-09-11 07:03:00-04:00,IMMU,neutral
662566.0,Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge,2017-08-28 14:30:00-04:00,IMMU,positive
662567.0,Mid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher,2017-08-28 12:13:00-04:00,IMMU,negative
662568.0,Mid-Morning Market Update: Markets Mostly Higher; Gilead Sciences To Buy Kite Pharma,2017-08-28 10:14:00-04:00,IMMU,neutral
662569.0,Mid-Afternoon Market Update: Crude Oil Down Over 2%; Abercrombie & Fitch Shares Surge Following Strong Q2 Results,2017-08-24 14:31:00-04:00,IMMU,positive
662570.0,Mid-Day Market Update: Guess? Climbs After Q2 Beat; Smucker Shares Slide,2017-08-24 12:18:00-04:00,IMMU,positive
662571.0,Immunomedics Spikes to High of $10.50 Following Block Trade of 435K+ Shares,2017-08-24 11:03:00-04:00,IMMU,negative
662572.0,Mid-Morning Market Update: Markets Edge Lower; Dollar Tree Profit Tops Expectations,2017-08-24 10:09:00-04:00,IMMU,positive
662573.0,Immunomedics Option Alert: Oct 20 $10 Calls Sweep (6) at the Bid: 1000 @ $0.517 vs 201 OI; Ref=$9.49 Signals,2017-08-23 11:30:00-04:00,IMMU,positive
662574.0,Immunomedics Publishes Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate 'Promising' Efficacy,2017-08-21 08:05:00-04:00,IMMU,neutral
662575.0,"Immunomedics Reports Q4 EPS $EPS $(0.48) May Not Compare To $(0.12) Est., Sales $0.6M May Not Compare To $2.33M Est.",2017-08-16 16:01:00-04:00,IMMU,neutral
662576.0,Immunomedics Reiterates Guidance On BLA Submission Timeline,2017-08-16 16:01:00-04:00,IMMU,neutral
662577.0,Immunomedics Reports Publication In 2 Cancer Journals Its Phase 2 Clinical Results With IMMU-132,2017-07-10 09:05:00-04:00,IMMU,negative
662578.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-10 08:24:00-04:00,IMMU,neutral
662579.0,Mid-Afternoon Market Update: L Brands Falls Following Disappointing Sales Report; Herman Miller Shares Surge,2017-07-06 14:34:00-04:00,IMMU,negative
662580.0,Mid-Day Market Update: Crude Oil Up Over 2%; Egalet Shares Plummet,2017-07-06 12:12:00-04:00,IMMU,negative
662581.0,Mid-Morning Market Update: Markets Open Lower; Liberty Interactive To Acquire HSN,2017-07-06 10:15:00-04:00,IMMU,positive
662582.0,"Companies Holding Shareholder Meetings Today Include: Allegiant Travel Co., Bed Bath & Beyond, Delek US Holdings, Gigamon, Guess, Heat Biologics, Immunomedics, Kadmon, Patterson-UTI, Tecogen, and Time Inc",2017-06-29 09:01:00-04:00,IMMU,neutral
662583.0,Mid-Day Market Update: Crude Oil Down Over 3%; Lipocine Shares Spike Higher,2017-06-20 12:01:00-04:00,IMMU,negative
662584.0,Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Expectations,2017-06-20 10:12:00-04:00,IMMU,positive
662585.0,22 Stocks Moving In Monday's Pre-Market Session,2017-06-12 08:31:00-04:00,IMMU,neutral
662586.0,Option Alert: Immunomedics Jun 8.0 Calls Sweep: 500 @  Above Ask!  $0.299: 1510 traded vs 4286 OI:  Earnings 8/16 After Close (est)  $7.59 Ref,2017-05-31 10:29:00-04:00,IMMU,positive
662587.0,"Benzinga's Top Upgrades, Downgrades For May 26, 2017",2017-05-26 09:31:00-04:00,IMMU,positive
662588.0,"Cowen & Co. Initiates Coverage On Immunomedics with Outperform Rating, Announces $15.00 Price Target",2017-05-26 06:56:00-04:00,IMMU,neutral
662589.0,"Immunomedics Reports Q3 EPS $(0.55) vs $(0.13) Est., Sales $1.3M vs $3.2M Est.",2017-05-10 16:11:00-04:00,IMMU,neutral
662590.0,20 Biggest Mid-Day Gainers For Friday,2017-05-05 12:27:00-04:00,IMMU,neutral
662591.0,Mid-Day Market Update: Crude Oil Up 2%; Brightcove Shares Plummet Following Q1 Results,2017-05-05 12:17:00-04:00,IMMU,negative
662592.0,Mid-Morning Market Update: Markets Open Mixed; Cognizant Earnings Beat Views,2017-05-05 10:07:00-04:00,IMMU,neutral
662593.0,UPDATE: Immunomedics Says 'Unwinding of the deal releases both companies from all material obligations subject to Court approval; Seattle Genetics maintains its existing equity stake in the Company',2017-05-05 08:51:00-04:00,IMMU,positive
662594.0,Immunomedics Announces CFO Michael Garone Will Be Named Interim CEO Once Settlement Deal is Finalized,2017-05-05 08:50:00-04:00,IMMU,neutral
662595.0,"Immunomedics is Targeting BLA Submission for IMMU-132 in TNBC by Late 2017, Early 2018",2017-05-05 08:49:00-04:00,IMMU,neutral
662596.0,Immunomedics Announces Mutual Deal with Seattle Genetics for Dissolving of Previously-Agreed Upon Exclusive Global Licensing Deal,2017-05-05 08:49:00-04:00,IMMU,positive
662597.0,Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan,2017-05-05 08:07:00-04:00,IMMU,positive
662598.0,Immunomedics Reports IMMU-132 is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy,2017-04-05 07:02:00-04:00,IMMU,negative
662599.0,Immunomedics Preclinical Study Shows Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan,2017-04-04 13:01:00-04:00,IMMU,positive
662600.0,Immunomedics Reports Sacituzumab Govitecan Has Potential To Provide Clinical Benefit To Chemosensitive Solid Tumors With Low and High Trop-2 Expression,2017-04-04 08:02:00-04:00,IMMU,positive
662601.0,ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno Oncology Collaboration,2017-03-23 06:02:00-04:00,IMMU,neutral
662602.0,Mid-Morning Market Update: Markets Open Higher; Genesco Profit Beats Views,2017-03-10 09:59:00-05:00,IMMU,positive
662603.0,"8-K from Seattle Genetics Shows Delaware Court of Chancery Issued Temporary Restraining Order Enjoining Taking Any Action in Furthering of Closing of Deal between Co., Immunomedics Related to IMMU-132",2017-03-10 07:38:00-05:00,IMMU,neutral
662604.0,"Immunomedics Shares Resume, Continuing Higher, Spike to Up 13%, Now Up 10%",2017-03-09 12:20:00-05:00,IMMU,positive
662605.0,"Immunomedics Shares Halted on Circuit Breaker, Now Up ~12%",2017-03-09 12:15:00-05:00,IMMU,positive
662606.0,"Immunomedics Licensing Deal Over Cancer Drug Temp. Halted, Bareed From Proceeding With Seattle Genetics Deal; Board Fight Over Immunomedics Spurred By Delaware Judge Ruling",2017-03-09 12:13:00-05:00,IMMU,negative
662607.0,"Immunomedics Shares Volatile, Now Up ~3%",2017-03-09 12:12:00-05:00,IMMU,positive
662608.0,"Immunomedics Sells off to Low of $4.79 on Volume, tjen Reverses to High of $5.27",2017-03-09 12:12:00-05:00,IMMU,negative
662609.0,Watch These 7 Huge Put Purchases In Monday Trade,2017-03-06 04:23:00-05:00,IMMU,positive
662610.0,Benzinga's Option Alert Recap From March 3,2017-03-03 16:40:00-05:00,IMMU,positive
662611.0,venBio Issues Release Highlighting Prelim. Results Indicate Immunomedics Holders Have Elected All 4 of Firm's Independent Director Nominees,2017-03-03 12:01:00-05:00,IMMU,neutral
662612.0,Immunomedics Says Co. Will Promptly Seek RRelief In Proceeding In Delaware Chancery Court While Co.. Continues To Take Steps To Protect Rights Of All Stockholders,2017-03-03 10:22:00-05:00,IMMU,positive
662613.0,Option Alert: Immersion Aug 7.5 Put; 3000 @Bid @$0.65,2017-03-03 09:51:00-05:00,IMMU,positive
662614.0,Immunomedics Holding Annual Shareholder Meeting Today,2017-03-03 08:02:00-05:00,IMMU,neutral
662615.0,"venBio Responds To Immunomedics PR This Morning, Calls IMMU's Comments 'Misleading', Encourages Shareholders To Vote For New Board Members",2017-03-02 13:59:00-05:00,IMMU,positive
662616.0,venBio Responds To Comments from Immunomedics,2017-03-02 13:52:00-05:00,IMMU,neutral
662617.0,Immunomedics Announces Revised Settlement Offer Rejected By venBio,2017-03-02 10:24:00-05:00,IMMU,negative
662618.0,Traders Circulating Chatter That Immunomedics Approached For Takeover,2017-03-02 09:47:00-05:00,IMMU,neutral
662619.0,Immunomedics Issues Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation,2017-02-27 08:02:00-05:00,IMMU,positive
662620.0,Immunomedics Reports Company's Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies,2017-02-23 11:33:00-05:00,IMMU,positive
662621.0,venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter,2017-02-22 08:32:00-05:00,IMMU,positive
662622.0,Immunomedics Files Lawsuit and motion for Injunctive Relief Against venBio  for Violations of Federal Securities Laws,2017-02-21 08:08:00-05:00,IMMU,neutral
662623.0,Immunomedics Says Sacituzumab Govitecan (Immu-132) is Active In Patients With Metastatic Urothelial Cancer,2017-02-17 12:07:00-05:00,IMMU,negative
662624.0,"Immunomedics To Launch REMAIN, An Overall Survival Study With Ceplene And Proleukin",2017-02-17 11:34:00-05:00,IMMU,neutral
662625.0,Immunomedics Sends Letter To Stockholders Urging Them To Vote For All Seven Board Members At Upcoming Annual Mtg,2017-02-15 16:34:00-05:00,IMMU,neutral
662626.0,Immunomedics Comments on venBio Lawsuit,2017-02-14 16:47:00-05:00,IMMU,negative
662627.0,"Immunomedics' Shareholder venBio Select Advisor Issues Statement In Opposition To Recent Partnership With Seattle Genetics, Files Motion For Injunction",2017-02-14 11:52:00-05:00,IMMU,neutral
662628.0,How Did Today's Zosano Pharma Short Call From Martin Shkreli Play Out?,2017-02-13 15:28:00-05:00,IMMU,positive
662629.0,"Martin Shkreli Says He Covered Immunomedics, Comments That He Would Not Buy Zosano Pharma As A Stock Offering Is Very Likely",2017-02-13 11:39:00-05:00,IMMU,neutral
662630.0,18 Stocks Moving In Monday's Pre-Market Session,2017-02-13 08:44:00-05:00,IMMU,neutral
662631.0,"venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders",2017-02-10 16:16:00-05:00,IMMU,neutral
662632.0,Shkreli: I'd Short Immunomedics On The Bounce,2017-02-10 16:08:00-05:00,IMMU,neutral
662633.0,"In A Facebook Post, Martin Shkreli Says He Would Short Immunomedics On Bounce, 'I cant believe they got $250 million for this irinotecan prodrug.  The workd has moved on from old chemo mechanisma to targeted/io. That'll be the last 250 they get.'",2017-02-10 15:13:00-05:00,IMMU,neutral
662634.0,20 Biggest Mid-Day Gainers For Friday,2017-02-10 13:25:00-05:00,IMMU,neutral
662635.0,Adam Feuerstein Tweets: There is some serious 3-D chess going on behind scenes w/ $IMMU.,2017-02-10 11:29:00-05:00,IMMU,negative
662636.0,30 Stocks Moving In Friday's Pre-Market Session,2017-02-10 08:39:00-05:00,IMMU,neutral
662637.0,"Immunomedics Enters Agreement With Seattle Genetics for Exclusive Rights to Commercialize Sacituzumab Govitecan, Immunomedic to Receive $250M Upfront, Sell $15M of Stock to Seattle Genetics",2017-02-10 06:55:00-05:00,IMMU,positive
662638.0,"Immunomedics Reports Q2 EPS $(0.23) vs $(0.13) Est, Reveneu $0.4M vs $3.1M Est",2017-02-09 16:01:00-05:00,IMMU,neutral
662639.0,"UPDATE: Immunomedics Says ISS, Glass Lewis 'reached wrong conclusion by over-focusing on the past'",2017-02-07 12:51:00-05:00,IMMU,negative
662640.0,"UPDATE: Immunomedics Says venBio 'Has NO Real Plan,' Says '100-Day Plan Has NO Substance'",2017-02-07 12:50:00-05:00,IMMU,negative
662641.0,UPDATE: Immunomedics Says Holders Should Vote FOR Co. Director Nominees on WHITE Proxy Card,2017-02-07 12:50:00-05:00,IMMU,neutral
662642.0,UPDATE: Immunomedics Says 'Stockholders Should Not Risk Giving venBio Directors Control of the Immunomedics Board of Directors',2017-02-07 12:49:00-05:00,IMMU,negative
662643.0,Immunomedics Reports Strong Encouragement for Shareholders to Reject venBio Nominees for Co. Board,2017-02-07 12:49:00-05:00,IMMU,positive
662644.0,ISS Endorses Full Slate of venBio Director Nominees at Immunomedics,2017-02-06 06:58:00-05:00,IMMU,positive
662645.0,"Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board, Deep Engagement in Robust, Value-Creating Strategic and CMC Processes",2017-02-02 16:22:00-05:00,IMMU,positive
662646.0,"6 Hot Stocks Among Shorts: IBM, Exxon Mobil And More",2017-01-31 13:38:00-05:00,IMMU,neutral
662647.0,Immunomedics Urges Voters To Vote On White Proxy Card,2017-01-30 09:03:00-05:00,IMMU,neutral
662648.0,Benzinga's Option Alert Recap From January 26,2017-01-26 16:49:00-05:00,IMMU,positive
662649.0,UPDATE: Immunomedics sacituzumab govitecan Data Release Last Week Has Attracted Greater Licensing Partnership Interest According To Dealreporter Contacts,2017-01-26 15:43:00-05:00,IMMU,positive
662650.0,Hearing Dealreporter Reporting Immunomedics Seeing Interest From Potential Partners,2017-01-26 15:41:00-05:00,IMMU,positive
662651.0,Option Alert: Immunomedics Feb 6.0 Calls Sweep: 500 @  ASK  $0.25: 500 traded vs 264 OI:  Earnings 2/1 After Close (est)  $4.70 Ref,2017-01-26 15:40:00-05:00,IMMU,positive
662652.0,Immunomedics spiking up 8.7% to a high of 4.82 on high volume,2017-01-26 15:35:00-05:00,IMMU,neutral
662653.0,Adam Feuerstein Tweets: @chasingthealpha $IMMU shareholder vote is Feb. 16. You can expect to see ISS recommendation about one week prior.,2017-01-25 11:27:00-05:00,IMMU,neutral
662654.0,TheStreet's Adam Feuerstein Publishes 'Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder',2017-01-25 11:04:00-05:00,IMMU,negative
662655.0,Immunomedics Mails Letter to Stockholders To Vote For All Seven Company Nominated Directors,2017-01-24 07:05:00-05:00,IMMU,neutral
662656.0,"Immunomedics Reports New Data for IMMU-132 at Investor R&D Day, Submission for Accelerated Approval Application to FDA for Patients with Metastatic TNBC Remains on Track for Mid-2017",2017-01-18 09:01:00-05:00,IMMU,positive
662657.0,Immunomedics Announces Antitumor Effect Of IMMU-132 Preclinical Study,2017-01-09 10:01:00-05:00,IMMU,neutral
662658.0,"Immunomedics Announces 4 New Directors, Leadership Succession Plan",2017-01-09 06:19:00-05:00,IMMU,positive
662659.0,Immunomedics Reports Achievement of Patient Enrollment Into Single-Arm Phase 2 Study With Sacituzumab Govitecan,2016-12-27 07:00:00-05:00,IMMU,neutral
662660.0,Immunomedics Announces Issuance of Patent for Antibody Drug Conjugate,2016-12-22 07:04:00-05:00,IMMU,neutral
662661.0,Immunomedics Announces Novel Immuno-Oncology Program Targeting Trop-2-Expressing Cancers,2016-12-12 07:04:00-05:00,IMMU,positive
662662.0,"San Antonio Breast Cancer Symposium (SABCS) Continues Today, Will Conclude December 10th",2016-12-09 08:44:00-05:00,IMMU,negative
662663.0,Hearing M&A Chatter Suggesting Immunomedics May Be Exploring A Sale,2016-12-06 09:42:00-05:00,IMMU,neutral
662664.0,UPDATE: venBio on Immunomedics: Believes Firm's Four Highly-Qualified Nominees Are Ideally Positioned to Effect Urgently Needed Change,2016-11-29 09:12:00-05:00,IMMU,positive
662665.0,venBio Issues Response Following Immunomedics' Postponing of Annual Meeting: Believes Company's Action Constitutes Unnecessary Delay and Hinders Stockholders' Ability to Voice Discontent,2016-11-29 09:12:00-05:00,IMMU,negative
662666.0,Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy Valtech Cardio,2016-11-28 09:56:00-05:00,IMMU,negative
662667.0,"Immunomedics Postpones 2016 Annual Meeting of Stockholders Until February 16, 2017",2016-11-28 07:13:00-05:00,IMMU,negative
662668.0,Option Alert: IMMU Dec16 4.0 Calls Sweep: 775 @  ASK  $0.149: 927 traded vs 36 OI:  Earnings 2/1 After Close (est)  $3.48 Ref,2016-11-22 13:23:00-05:00,IMMU,positive
662669.0,Watch These 7 Huge Call Purchases In Friday Trade,2016-11-18 02:06:00-05:00,IMMU,positive
662670.0,Option Alert: IMMU Dec16 3.0 Calls Sweep: 500 @  ASK  $0.35: 1751 traded vs 446 OI:  Earnings 2/1 After Close (est)  $3.06 Ref,2016-11-17 09:34:00-05:00,IMMU,positive
662671.0,venBio Select Advisor Reports 9% Stake In Immunomedics 13D Filing,2016-11-16 15:40:00-05:00,IMMU,neutral
662672.0,"Immunomedics Reports Issuance of US Patent 9,492,566 Protecting Use of IMMU-132 for Treatment of Patients with Trop-2-positive Cancers",2016-11-15 07:06:00-05:00,IMMU,neutral
662673.0,"Immunomedics Reports Q1 EPS $(0.17) vs. Est. $(0.14), Rev. $700K vs. Est. $3.1M",2016-11-02 16:41:00-04:00,IMMU,neutral
662674.0,Immunomedics Engages Greenhill & Co. as Strategic Advisor To Assist In Ongoing Efforts To Out-License sacituzumab govitecan,2016-10-24 16:31:00-04:00,IMMU,positive
662675.0,"Immunomedics Announces Patents For Antibody Drug Conjugates, Vaccines for Cancer Therpay",2016-10-19 07:04:00-04:00,IMMU,negative
662676.0,Mid-Day Market Update: Advanced Micro Devices Climbs After Chip Deal With Alibaba; Ocean Power Technologies Shares Slide,2016-10-14 12:20:00-04:00,IMMU,positive
662677.0,Jefferies Sees Accelerated Approval Of Immunomedics' IMMU-132 'Not A Stretch',2016-10-06 11:43:00-04:00,IMMU,positive
662678.0,Jefferies Assumes Immunomedics at Buy,2016-10-06 07:16:00-04:00,IMMU,neutral
662679.0,Mid-Afternoon Market Update: Dow Gains 125 Points; Net 1 Shares Spike Higher,2016-10-05 14:41:00-04:00,IMMU,positive
662680.0,12 Biggest Mid-Day Losers For Wednesday,2016-10-05 13:13:00-04:00,IMMU,negative
662681.0,Mid-Day Market Update: Crude Oil Up Over 2%; AZZ Shares Drop Following Q2 Results,2016-10-05 12:21:00-04:00,IMMU,negative
662682.0,Buyers Of Offering In Immunomedics Underwater,2016-10-05 11:37:00-04:00,IMMU,neutral
662683.0,Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q2 Views,2016-10-05 10:19:00-04:00,IMMU,positive
662684.0,Immunomedics Reports $30M Financing at $3/Unit,2016-10-05 08:09:00-04:00,IMMU,neutral
662685.0,10 Stocks Which Rallied Three Days On Increasing Volume,2016-09-19 09:26:00-04:00,IMMU,neutral
662686.0,15 Biggest Mid-Day Gainers For Thursday,2016-08-18 13:49:00-04:00,IMMU,neutral
662687.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-18 08:40:00-04:00,IMMU,neutral
662688.0,Immunomedics Reports Preclinical Study on Enhancing IMMU-132 Activity in SN-38-Resistant Cancer Cells Increased Median Survival of Mice,2016-08-18 07:04:00-04:00,IMMU,negative
662689.0,"Immunomedics Reports Q4 Loss/Share $(0.17) vs Est Loss/Share ($0.11), Rev $0.9M vs $1.2M Est",2016-08-17 16:01:00-04:00,IMMU,neutral
662690.0,10 Biggest Mid-Day Gainers For Tuesday,2016-06-28 12:33:00-04:00,IMMU,neutral
662691.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-06-28 08:20:00-04:00,IMMU,neutral
662692.0,Immunomedics Announces Patent For Sacituzumab Govitecan,2016-06-28 07:04:00-04:00,IMMU,neutral
662693.0,Wells Fargo Downgrades Immunomedics to Market Perform,2016-06-21 11:10:00-04:00,IMMU,positive
662694.0,Immunomedics Names Michael R. Garone as New CFO,2016-06-21 08:05:00-04:00,IMMU,neutral
662695.0,Immunomedics Names Michael Garone CFO,2016-06-21 08:00:00-04:00,IMMU,neutral
662696.0,5 Stocks Moving In Friday's After-Hours Session,2016-06-10 17:13:00-04:00,IMMU,neutral
662697.0,Option Alert: IMMU Jun16 4.5 Puts Sweep: 500 @  ASK  $1.30: 1000 traded vs 1641 OI: $3.29 Ref,2016-06-09 10:03:00-04:00,IMMU,positive
662698.0,"Immunomedics Reports IMMU-132 Shows Efficacy, Safety in Non-Small Cell Lung Cancer Patients with Multiple Prior Treatments",2016-06-06 15:15:00-04:00,IMMU,negative
662699.0,"Immunomedics Announces Sacituzumab Govitecan is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer, Median Progression-Free Survival Of 3.6 Months",2016-06-06 07:05:00-04:00,IMMU,negative
662700.0,Mid-Afternoon Market Update: Gold Rises 2.5%; Ambarella Shares Climb On Upbeat Results,2016-06-03 14:34:00-04:00,IMMU,positive
662701.0,Mid-Day Market Update: First Marblehead Surges Following Acquisition News; Immunomedics Shares Drop,2016-06-03 12:01:00-04:00,IMMU,neutral
662702.0,Mid-Morning Market Update: Markets Open Lower; Broadcom Profit Beats Expectations,2016-06-03 10:06:00-04:00,IMMU,positive
662703.0,UPDATE:  Immunomedics Says No Question was Raised on Quality of Results,2016-06-03 09:20:00-04:00,IMMU,negative
662704.0,Immunomedics Says  Triple-Negative Breast Cancer Presentation was Cancelled Following Complaint Company Violated Embargo,2016-06-03 09:19:00-04:00,IMMU,negative
662705.0,12 Stocks Moving In Friday's Pre-Market Session,2016-06-03 08:18:00-04:00,IMMU,neutral
662706.0,Option Alert: IMMU Jan17 5.5 Calls Sweep: 742 @  ASK  $1.55: 5013 traded vs 65 OI: $5.30 Ref,2016-06-02 15:04:00-04:00,IMMU,positive
662707.0,Mid-Morning Market Update: Markets Open Lower; Joy Global Profit Tops Expectations,2016-06-02 10:01:00-04:00,IMMU,positive
662708.0,Top 3 Pre-Market Losers Today,2016-05-23 09:18:00-04:00,IMMU,negative
662709.0,12 Stocks Moving In Monday's Pre-Market Session,2016-05-23 08:26:00-04:00,IMMU,neutral
662710.0,Option Alert: IMMU Aug16 7.0 Calls: 583 @  ASK  $0.10: 584 traded vs 6 OI: $3.96 Ref,2016-05-19 09:49:00-04:00,IMMU,positive
662711.0,"Jefferies Upgrades Immunomedics to Buy, Raises PT to $5.00",2016-05-06 07:02:00-04:00,IMMU,neutral
662712.0,"Immunomedics Reports Q3 EPS $(0.15) vs $(0.13) Est., Sales $900K vs $2.13M Est.",2016-05-04 16:38:00-04:00,IMMU,neutral
662713.0,Immunomedics Reports Abstract on IMMU-132 in Patients with Triple-Negative Breast Cancer Selected for Best of ASCO Program,2016-05-02 12:22:00-04:00,IMMU,negative
662714.0,Immunomedics Reports Responses With Sacituzumab Govitecan in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor Therapy,2016-04-29 11:46:00-04:00,IMMU,negative
662715.0,Immunomedics Reports Winning of US Patent for Novel Immuno-Oncology Agents for Cancer Therapy,2016-04-20 07:03:00-04:00,IMMU,positive
662716.0,"Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains",2016-04-18 13:03:00-04:00,IMMU,positive
662717.0,Immunomedics Announces Positive Results For IMMU-114 Phase 1 Trial,2016-04-18 07:03:00-04:00,IMMU,positive
662718.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-03-15 08:20:00-04:00,IMMU,neutral
662719.0,3 Stocks Witnessing Big Moves After Hours,2016-03-14 17:12:00-04:00,IMMU,neutral
662720.0,Immunomedics Offers Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients with Advanced Pancreatic Cancer,2016-03-14 16:31:00-04:00,IMMU,negative
662721.0,Immunomedics Issued US Patent Related To Method Of Use Of Proprietary Anti-Histone Antibody,2016-03-08 07:05:00-05:00,IMMU,neutral
662722.0,"Immunomedics Announces Issuance of U.S. Patent for Company's New Patent Family ""Methods of Treating Rapidly Progressive Glomerulonephritis Using Chimeric and Humanized Anti-Histone Antibodies""",2016-03-08 07:04:00-05:00,IMMU,neutral
662723.0,Immunomedics Spikes to High of $2.15 on Volume,2016-02-09 14:50:00-05:00,IMMU,neutral
662724.0,"Immunomedics Reports Q2 EPS $(0.15) vs $(0.14) Est., Sales $700K vs $1.23M Est.",2016-02-03 16:00:00-05:00,IMMU,neutral
662725.0,"Immunomedics Reports New Patent Covering the Use of Antibody-SN-38 Conjugates Combination, Company Working With FDA On Phase 3 Trial Design In Patients With Metastatic Colorectal Cancer",2016-01-05 07:21:00-05:00,IMMU,negative
662726.0,"UPDATE: Immunomedics Reports Objective Response Rate 31%, 78% Confirmed, Median Progression-Free Survival 6 Months, 58% Maturity",2015-12-10 08:40:00-05:00,IMMU,neutral
662727.0,Immunomedics Reports Positive Results With Sacituzumab Govitecan in Heavily Pre-Treated Metastatic Triple-Negative Breast Cancer Patients,2015-12-10 08:31:00-05:00,IMMU,negative
662728.0,Immunomedics Reports Initial Results of a Phase I First-In-Man Study With IMMU-114 in Hematologic Malignancies; 50% Of Patients Show Objective Evidence Of Treatment Activity,2015-12-07 07:01:00-05:00,IMMU,neutral
662729.0,Immunomedics Shares Tumble 7+% Following Earlier Wells Fargo Downgrade,2015-12-04 12:32:00-05:00,IMMU,positive
662730.0,Immunomedics Reports Sacituzumab Govitecan Is Synergistic With Chemotherapeutics That Target Cell Division in Triple-Negative Breast Cancer,2015-11-09 07:13:00-05:00,IMMU,negative
662731.0,Immunimedics Reports Q1 EPS Loss $0.16 Vs Est $0.14,2015-11-04 16:02:00-05:00,IMMU,negative
662732.0,Immunomedics Spikes to High on Volume,2015-10-27 14:13:00-04:00,IMMU,neutral
662733.0,"Immunomedics Share Spike Higher, Up ~17.50%",2015-10-27 14:13:00-04:00,IMMU,positive
662734.0,Immunomedics Reports Durable Responses In Patients With Advanced Solid Cancers After Therapy With Sacituzumab,2015-10-19 14:37:00-04:00,IMMU,positive
662735.0,Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan,2015-10-19 14:37:00-04:00,IMMU,positive
662736.0,Option Alert: $IMMU Oct $1.5 Call Sweep; 2455 Contracts @Ask @ $0.60; Now $2.08,2015-10-06 15:50:00-04:00,IMMU,positive
662737.0,Immunomedics Spikes to High on Volume,2015-10-06 14:00:00-04:00,IMMU,neutral
662738.0,Mid-Morning Market Update: Markets Open Higher; Media General To Acquire Meredith For $2.4B,2015-09-08 10:27:00-04:00,IMMU,neutral
662739.0,Morning Market Gainers,2015-09-08 09:45:00-04:00,IMMU,neutral
662740.0,Benzinga's Top #PreMarket Losers,2015-09-08 08:28:00-04:00,IMMU,negative
662741.0,Benzinga's Top #PreMarket Gainers,2015-09-08 08:15:00-04:00,IMMU,positive
662742.0,Immunomedics +30% Premarket Following Announcement of Interim Phase 2 Results With Sacituzumab Govitecan in Lung Cancers,2015-09-08 07:54:00-04:00,IMMU,neutral
662743.0,US Stock Futures Signal Higher Start On Wall Street,2015-09-08 07:07:00-04:00,IMMU,neutral
662744.0,Immunomedics Reports Interim Phase 2 Results With Sacituzumab Govitecan in Lung Cancers,2015-09-08 07:00:00-04:00,IMMU,neutral
662745.0,Option Alert: $IMMU Sep $2 Call Sweep; 1629 Contracts @Ask @$0.25; Now $1.95,2015-08-21 12:01:00-04:00,IMMU,positive
662746.0,Immunomedics Reports Inline Q2 Loss $0.13,2015-08-19 16:00:00-04:00,IMMU,negative
662747.0,Immunomedics Appoints Arthur S. Kirsch as Director,2015-08-19 07:03:00-04:00,IMMU,neutral
662748.0,Immunomedics Shares Fall to Low; May be Attributed to Seeking Alpha Post,2015-08-18 13:45:00-04:00,IMMU,neutral
662749.0,Immunomedics Announces Additional Patent Protection For Antibody Drug Program,2015-08-18 07:04:00-04:00,IMMU,neutral
662750.0,Immunomedics Extends U.S. Patent Protection for Antibody-Drug Conjugate Program to 2033,2015-08-18 07:00:00-04:00,IMMU,positive
662751.0,Immunomedics Reports Orphan Drug Designation for Veltuzumab for the Treatment of Immune Thrombocytopenia,2015-08-04 08:30:00-04:00,IMMU,positive
662752.0,Keep An Eye On These 6 Stocks Monday Morning,2015-08-02 10:03:00-04:00,IMMU,neutral
662753.0,"Immunomedics Downgraded At Jefferies, Firm Removes Epratuzumab Revenues From Model",2015-07-29 09:58:00-04:00,IMMU,neutral
662754.0,"Jefferies Downgrades Immunomedics to Hold, Lowers PT to $2.00",2015-07-29 06:44:00-04:00,IMMU,negative
662755.0,Stocks Hitting 52-Week Lows,2015-07-28 10:17:00-04:00,IMMU,negative
662756.0,Morning Market Losers,2015-07-28 09:51:00-04:00,IMMU,negative
662757.0,Shares of Immunomedics Plunge ~46% in Pre-Market Action Following News from Co.'s Licensing Partner UCB Phase III Trial for Epratuzumab in Lupus Did Not Hit Statistically Significant Results,2015-07-28 07:15:00-04:00,IMMU,positive
662759.0,Option Alert: Immunomedics Jul $7 Call; 2513 Contracts Traded vs 2088 OI; Now $4.14,2015-06-17 13:42:00-04:00,IMMU,positive
662760.0,Cancer Drug Conference Gives Sector A Boost,2015-06-12 13:41:00-04:00,IMMU,negative
662761.0,Immunomedics Spikes Higher,2015-06-05 14:42:00-04:00,IMMU,neutral
662762.0,Immunomedics Announces Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer,2015-06-02 10:26:00-04:00,IMMU,negative
662763.0,UPDATE: Immunomedics Lead Antibody-Drug Conjugate Demonstrated Mid-Stage Study Promising Anti-Tumor Activity In Lung Cancer,2015-06-02 10:20:00-04:00,IMMU,negative
662764.0,Immunomedics Reports Durable Repsonses On Metastantic Lung Cancer Patients,2015-06-02 10:15:00-04:00,IMMU,negative
662765.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,IMMU,neutral
662766.0,Immunomedics Presents Promising Results With Sacituzumab Govitecan in Patients With Metastatic Gastrointestinal Cancers,2015-06-01 09:07:00-04:00,IMMU,positive
662767.0,Immunomedics Announces Complete Responses in Patients With Metastatic Triple-Negative Breast Cancer Proceeding Sacituzumab Govitecan Treatment,2015-06-01 07:01:00-04:00,IMMU,negative
662769.0,Immunomedics Granted Fast Track Designation By FDA For Sacituzumab Govitecan,2015-05-15 12:31:00-04:00,IMMU,positive
662770.0,Immunomedics Extends Patent Production In U.S. For Sacituzumab Govitecan to 2033,2015-05-12 08:33:00-04:00,IMMU,positive
662771.0,"Immunomedics Reports Inline Q3 EPS Loss $0.13, Sales $1.18M Vs Est $1.07M",2015-05-06 16:01:00-04:00,IMMU,negative
662772.0,Benzinga's Top #PreMarket Gainers,2015-05-04 08:14:00-04:00,IMMU,positive
662773.0,"Shares of Immunomedics Resume Trade; Stock Now Ticker Off Session Low, at $3.83",2015-04-20 15:37:00-04:00,IMMU,neutral
662774.0,"Shares of Immunomedics Plunge Below $4.20 Level, Stock Now Down to $3.72",2015-04-20 15:34:00-04:00,IMMU,positive
662776.0,"Immunomedics Reports Patients with Advanced Breast, Lung, Esophageal, Colorectal Cancers Respond to Co.'s Novel Antibody-Direct Chemotherapy",2015-04-20 15:13:00-04:00,IMMU,positive
662777.0,Immunomedics Presents Updated Results Sacituzumab Govitecan In Lung Cancer,2015-02-19 14:31:00-05:00,IMMU,negative
662778.0,Immunomedics Reports Q2 EPS Loss $0.12 Vs Est Loss $0.13,2015-02-04 16:18:00-05:00,IMMU,negative
662779.0,Immunomedics Reports Dismissal of Putative Class Act Suit,2015-01-29 08:30:00-05:00,IMMU,neutral
662780.0,Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers,2015-01-20 08:31:00-05:00,IMMU,neutral
662781.0,Benzinga's Top Initiations,2015-01-07 09:20:00-05:00,IMMU,positive
662782.0,Wells Fargo Initiates Immunomedics At Outperform,2015-01-07 09:07:00-05:00,IMMU,positive
662783.0,Wells Fargo Initiates Coverage on Immunomedics at Outperform,2015-01-07 06:59:00-05:00,IMMU,positive
662784.0,Immunomedics Names Francois Wilhelm Chief Medical Officer,2015-01-06 08:32:00-05:00,IMMU,neutral
662785.0,Mid-Morning Market Update: Markets Open Lower; General Motors U.S. Sales Surge 19%,2015-01-05 10:28:00-05:00,IMMU,negative
662786.0,Morning Market Movers,2015-01-05 09:47:00-05:00,IMMU,neutral
662787.0,"Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More",2015-01-05 09:31:00-05:00,IMMU,neutral
662788.0,Immunomedics Reports Winning of Fast Track Designation for IMMU-132 for Triple-Negative Breast Cancer,2015-01-05 08:32:00-05:00,IMMU,negative
662789.0,"8-K from Immunomedics Shows Arbitrator Related to Takeda License Deal Termination Awarded No Money, All Rights to Veltuzumab Reverted Back to Co.",2014-12-17 16:37:00-05:00,IMMU,positive
662790.0,Immunomedics Reports Preliminary Results From Pretargeted Imaging Study in Patients With Metastatic Breast Cancer,2014-12-15 08:44:00-05:00,IMMU,negative
662791.0,"Immunomedics Announces Expanded Phase 1/2 Trials Which Confirm Activity, Good Safety Profile of IMMU-132",2014-12-12 08:31:00-05:00,IMMU,positive
662792.0,"Option Alert: Immunomedics May $7 Call; 1,785 Contract Trade at Ask @$0.35; Currently $4.37",2014-12-05 12:38:00-05:00,IMMU,positive
662793.0,"Immunomedics Reports Outcome of '14 Annual Meeting of Shareholders: Dr. David Goldenberg Reappointed as Chair, Brian Markison as Lead Independent Director",2014-12-03 13:02:00-05:00,IMMU,neutral
662794.0,Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus,2014-11-21 08:31:00-05:00,IMMU,neutral
662795.0,Immunomedics Receives Third Edison Patent Award From Research & Development Council of New Jersey ,2014-11-07 08:37:00-05:00,IMMU,positive
662796.0,"Immunomedics, Inc. Reports Q1 EPS of $(0.13) vs $(0.12) Est; Revenue of $1.10M vs $1.14M Est",2014-11-05 16:00:00-05:00,IMMU,neutral
662797.0,UPDATE: Immunomedics Says ADC Well Tolerated At Phase 2 Dose,2014-10-29 15:04:00-04:00,IMMU,positive
662798.0,Immunomedics Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers,2014-10-29 15:03:00-04:00,IMMU,positive
662799.0,Immunomedics To Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates At Upcoming Conferences ,2014-10-22 08:36:00-04:00,IMMU,neutral
662800.0,Immunomedics Announces European Orphan Drug Designation for Isactuzumab Govitecan for Pancreatic Cancer Treatment,2014-10-20 08:36:00-04:00,IMMU,negative
662801.0,Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody ,2014-09-26 08:33:00-04:00,IMMU,positive
662802.0,"Jefferies Initiates Coverage on Immunomedics, Inc. at Buy, Announces $6.00 PT",2014-09-23 06:06:00-04:00,IMMU,neutral
662803.0,"Immunomedics, Inc. Reports Q4 EPS of $(0.13) vs $(0.12) Est; Revenue of $1.19M vs $1.20M Est",2014-08-25 16:00:00-04:00,IMMU,neutral
662804.0,"Earnings Scheduled For August 25, 2014 ",2014-08-25 04:29:00-04:00,IMMU,neutral
662805.0,Immunomedics Announces Orphan Drug Designation for IMMU-132 for Pancreatic Cancer,2014-06-09 08:32:00-04:00,IMMU,negative
662806.0,Immunomedics Reports Development of Improved Cancer Immunotherapy at ASCO 2014,2014-06-01 10:08:00-04:00,IMMU,negative
662807.0,Immunomedics Reports Final Efficacy Results of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer ,2014-06-01 09:58:00-04:00,IMMU,negative
662808.0,Immunomedics Offers Results with IMMU-132 in Patients with Pancreatic Cancer,2014-05-20 13:32:00-04:00,IMMU,negative
662809.0,"Release from Immunomedics Shows Updated Results from 90Y-Clivatuzumab Tetraxetan, Overall Survival of 7.9 Mos. Receiving Multiple Cycles",2014-05-19 11:03:00-04:00,IMMU,neutral
662810.0,"Immunomedics Announces US Patent for IMMU-114, Will Expire May 26th, 2026",2014-05-13 08:34:00-04:00,IMMU,neutral
662811.0,"Immunomedics, Inc. Reports Q3 EPS of $(0.11), Inline; Revenue of $1.20M vs $1.06M Est",2014-05-07 16:35:00-04:00,IMMU,neutral
662812.0,Immunomedics Prices 9M Shares at $3.35/Share,2014-05-02 09:20:00-04:00,IMMU,positive
662813.0, Immunomedics Announces Proposed Public Offering Of Common Stk,2014-05-01 16:13:00-04:00,IMMU,neutral
662814.0,"Immunomedics Highlights Clinical Pipeline for Solid Cancer, Lupus Therapy at R&D Day",2014-04-23 12:31:00-04:00,IMMU,negative
662815.0,"Option Alert: ImmunoGen Apr $14 Call; 1,700 Contracts Traded vs 80 OI; Currently $14.53",2014-04-09 10:24:00-04:00,IMMU,positive
662816.0,"Immunomedics Reports Multiple Partial Responses with IMMU-132 in Solid Cancers, Phase I/II Indicate Overall 77% Disease Control Rate",2014-04-07 11:01:00-04:00,IMMU,positive
662817.0,Immunomedics to Provide Clinical Trial on Solid-Tumor Antibody-Drug Conjugates at Cancer Conference,2014-03-31 08:36:00-04:00,IMMU,negative
662818.0,"UPDATE: Immunomedics Extends Patnet Life to May 1st, 2032",2014-02-26 11:14:00-05:00,IMMU,positive
662819.0,Immunomedics Extends Patent Life on Therapeutic Antibodies ,2014-02-26 11:14:00-05:00,IMMU,positive
662820.0,"Immunomedics, Inc. Reports Q2 EPS of $(0.10), Down 43% YOY; Revenue of $1.20M vs $1.20M Est",2014-02-10 16:14:00-05:00,IMMU,neutral
662821.0,Benzinga's Top #PreMarket Gainers,2014-01-10 08:16:00-05:00,IMMU,positive
662822.0,UPDATE: Immunomedics Shares Rise 20% After-Hours on Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan,2014-01-09 17:23:00-05:00,IMMU,positive
662823.0,Immunomedics Announces Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan in Patients With Pancreatic Cancer,2014-01-09 16:07:00-05:00,IMMU,negative
662824.0,"Immunomedics Reports Initiation of Phase 3 Trial of Clivatuzumab Tetraxetan, Says Primary Endpoint Will Be Overall Survival",2014-01-09 16:04:00-05:00,IMMU,neutral
662825.0,Immunomedics Announces U.S. Patent for Antibody-SN-38 Conjugates,2013-12-31 08:37:00-05:00,IMMU,neutral
662826.0,Immunomedics Awarded US Patent for Antibody-SN-38 Conjugates ,2013-12-31 08:34:00-05:00,IMMU,positive
662827.0,"Immunomedics Says Veltuzumab Overall Objective Response Rate 49%, Showed Activity in All Dose Levels Tested",2013-12-09 08:33:00-05:00,IMMU,neutral
662828.0,Immunomedics Confirms Orphan Drug Designation for IMMU-132,2013-12-04 08:30:00-05:00,IMMU,neutral
662829.0,Bloomberg Reporting Immunomedics Receives Orphan Drug Designation for Lung Cancer Treatment,2013-12-03 12:04:00-05:00,IMMU,negative
662830.0,Immunomedics Reports Key Patent for TROP-2 Antibody,2013-11-05 08:32:00-05:00,IMMU,neutral
662831.0,"Immunomedics, Inc. Reports Q1 EPS of $(0.05) vs $(0.09) Est; Revenue of $5.50M vs $1.42M Est",2013-11-04 16:24:00-05:00,IMMU,neutral
662832.0,Immunomedics (IMMU) Majority-owned Subsidiary Awarded US Patent for New Vaccine Technology Targeting Dendritic Cells,2013-10-23 10:41:00-04:00,IMMU,positive
662833.0,Immunomedics Says 90 Y-Clivatuzumab Tetraxetan in Combo with Low-Dose Gemcitabine Active,2013-10-23 08:32:00-04:00,IMMU,positive
662834.0,"Immunomedics Announces Multiple Objective Responses in Solid Cancers with IMMU-132, Trial Expanding to Phase 2",2013-10-22 12:32:00-04:00,IMMU,positive
662835.0,UPDATE: Immunomedics Announces Termination of Agreement and Return of Worldwide Rights to Veltuzumab for All Non-Cancer Indications,2013-10-09 17:02:00-04:00,IMMU,positive
662836.0,Immunomedics Confirms Funding Over $1.6M from Department of Defense for Milatuzumab in Lupus,2013-09-30 12:01:00-04:00,IMMU,positive
662837.0,"Immunomedics Says IMMU-130 Produced Partial Response in One Patient, Response Duration 4.7 Months",2013-09-30 08:32:00-04:00,IMMU,neutral
662838.0,"RF Lafferty Initiates Coverage on Immunomedics, Inc. at Buy, Announces $8.00 PT",2013-09-10 10:13:00-04:00,IMMU,neutral
662839.0,Benzinga's Top Pre-Market Losers,2013-09-06 08:11:00-04:00,IMMU,negative
662840.0,"Immunomedics Announces Gorman to Retire, Names Peter Pfreundschuh as New CFO",2013-09-03 16:02:00-04:00,IMMU,neutral
662841.0,Immunomedics Announces Update To Drug Studies,2013-08-14 08:34:00-04:00,IMMU,neutral
662842.0,Immunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs to Phase II Clinical Trials ,2013-08-12 08:32:00-04:00,IMMU,negative
662843.0,Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases ,2013-07-16 08:31:00-04:00,IMMU,negative
662844.0,Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies ,2013-07-03 09:15:00-04:00,IMMU,negative
662845.0,Afternoon Market Gainers,2013-06-21 12:45:00-04:00,IMMU,neutral
662846.0,Immunomedics Says UCB Offers New Results from Phase 2B Open-Label Extension Study of Epratuzumab in SLE,2013-06-13 08:46:00-04:00,IMMU,neutral
662847.0,Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in Non-Hodgkin Lymphoma,2013-06-11 08:38:00-04:00,IMMU,positive
662848.0,90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP,2013-06-10 16:35:00-04:00,IMMU,positive
662849.0,"Immunomedics Announces New Novel Dual System for Tumor Detection, Imaging",2013-06-10 08:19:00-04:00,IMMU,negative
662850.0,Afternoon Market Gainers ,2013-05-30 14:24:00-04:00,IMMU,neutral
662851.0,Immunomedics Offers Progress of Antibody-Drug Conjugate Programs at NY Biotech Association Conference,2013-05-30 08:36:00-04:00,IMMU,positive
662852.0,"Immunomedics, Inc. Reports Q3 EPS of $0.11 vs $(0.10) Est; Revenue of $1.74M vs $970.0K Est",2013-05-08 16:56:00-04:00,IMMU,neutral
662853.0,Immunomedics Reports Three New Patent Wins,2013-05-07 08:34:00-04:00,IMMU,positive
662854.0,Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors,2013-04-10 08:32:00-04:00,IMMU,positive
662855.0,Immunomedics Announces First Results of Labetuzumab-SN-38 in Colorectal Cancer Study,2013-04-09 08:34:00-04:00,IMMU,negative
662856.0,"Immunomedics Settles FINRA Arbitration Proceedings, to Receive Gross Settlement of $18M",2013-04-01 17:04:00-04:00,IMMU,negative
662857.0,"Immunomedics Closes Offering, Sold 7M Shares at $2.30/Share",2013-02-27 16:21:00-05:00,IMMU,positive
662858.0,Stocks Hitting 52-Week Lows,2013-02-22 10:18:00-05:00,IMMU,negative
662859.0,Immunomedics Prices 6.09M Shares at $2.30/Share,2013-02-22 09:21:00-05:00,IMMU,positive
662860.0,Algeta Initiates Research Program to Evaluate Potential of Targeted Thorium Conjugate Based on Immunomedics' Anti-Cd22,2013-01-28 05:59:00-05:00,IMMU,neutral
662861.0,Immunomedics Announces U.S. Patent for Hexavalent DOCK-AND-LOCK Complexes,2013-01-08 08:32:00-05:00,IMMU,neutral
662862.0,Immunomedics Wins New Patent for Antibodies Targeting CD19,2012-12-21 08:43:00-05:00,IMMU,positive
662863.0,Immunomedics Offers Clinical Updates on Subcutaneous Injections of Veltuzumab,2012-12-11 10:07:00-05:00,IMMU,neutral
662864.0,Immunomedics Offers Updated Clinical Results on Potential New Treatment Regiment for NHL,2012-12-11 08:59:00-05:00,IMMU,neutral
662865.0,Immunomedics Says Addition of Epratuzumab in Combination Chemotherapy Could Be Beneficial to Acute Lymphocytic Leukemia Patients,2012-12-10 13:04:00-05:00,IMMU,positive
662866.0,Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated,2012-12-10 08:40:00-05:00,IMMU,neutral
662867.0,Immunomedics Reports Clinically Meaningful Improvements for Lupus Patients Treated with Epratuzumab,2012-11-13 09:11:00-05:00,IMMU,positive
662868.0,Immunomedics Files 20M Share Securities Shelf,2012-10-11 16:10:00-04:00,IMMU,positive
662869.0,Immunomedics Discovers Potential New Therapy for Graft-Versus-Host Disease ,2012-10-09 12:03:00-04:00,IMMU,neutral
662870.0,"Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)",2012-10-03 14:57:00-04:00,IMMU,positive
662871.0,UPDATE: Wedbush Securities Downgrades Immunomedics to Neutral; Lacking Catalysts  ,2012-08-28 12:53:00-04:00,IMMU,positive
662872.0,Wedbush Securities Downgrades Immunomedics from Outperform to Neutral,2012-08-28 07:29:00-04:00,IMMU,positive
662873.0,Immunomedics Reports Q4 EPS $-0.10 vs $-0.09 Est; Revenues $1M vs $1.66M Est,2012-08-23 16:19:00-04:00,IMMU,neutral
662874.0,"Cantor Rates Immunogen New Hold, Price Target $15",2012-06-13 16:10:00-04:00,IMMU,neutral
662875.0,Immunomedics Reports Updated Results From Phase I Pretargeting Therapy Study in Colorectal Cancer  ,2012-06-13 14:18:00-04:00,IMMU,negative
662876.0,Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma,2012-06-13 09:01:00-04:00,IMMU,neutral
662877.0,Immunomedics Reports Development of a New Labeling Kit for Attaching Fluorine-18 to Peptides and Temperature-Sensitive,2012-06-11 12:31:00-04:00,IMMU,neutral
662878.0,Immunomedics Reports Final Survival Data From Two-Part Pancreatic Cancer Study With Yttrium-90-Labeled Clivatuzumab Tetraxetan Combined With Gemcitabine ,2012-06-04 09:04:00-04:00,IMMU,negative
662879.0,"Oppenheimer Maintains Outperform Rating, $6 PT for Immunomedics",2012-05-11 19:26:00-04:00,IMMU,neutral
662880.0,Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer ,2012-04-02 09:05:00-04:00,IMMU,negative
662881.0,Immunomedics Reports Q2 EPS $0.27 vs $(0.08) Est; Revs $29.7M vs $11.47M Est,2012-02-08 08:56:00-05:00,IMMU,neutral
662882.0,Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy,2012-01-31 08:31:00-05:00,IMMU,positive
662883.0,Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan,2012-01-20 12:09:00-05:00,IMMU,neutral
662884.0,Immunomedics Reports Clivatuzumab-Based Blood Test Highly Sensitive and Specific for Early-Stage Pancreatic Cancer Detection,2012-01-18 08:30:00-05:00,IMMU,negative
662885.0,Wedbush Reports Update on Immunomedics' Restructuring Plan with UCB SA,2011-12-29 08:46:00-05:00,IMMU,neutral
662886.0,Oppenheimer Maintains Outperform on Immunomedics After Partnership Restructuring,2011-12-28 12:21:00-05:00,IMMU,neutral
662887.0,Immunomedics and UCB Announce Restructuring of Epratuzumab License Agreement; Immunomedics Will Receive $30M,2011-12-28 06:53:00-05:00,IMMU,positive
662888.0,Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing  ,2011-12-14 08:31:00-05:00,IMMU,positive
662889.0,Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing,2011-12-14 08:30:00-05:00,IMMU,positive
662890.0,Notable Call Options Activity in Immunomedics,2011-12-13 15:21:00-05:00,IMMU,neutral
662891.0,Immunomedics Announces Results From Two Clinical Trials at Hematology Conference,2011-12-13 08:32:00-05:00,IMMU,neutral
662892.0,Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas  ,2011-12-13 06:47:00-05:00,IMMU,positive
662893.0,Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune,2011-12-12 13:31:00-05:00,IMMU,positive
662894.0,Immunomedics Awarded Additional U.S. Patent for Anti-CD20 Treatment of Autoimmune Diseases,2011-11-15 08:32:00-05:00,IMMU,positive
662895.0,Immunomedics Receives Thomas Alva Edison Patent Award From Research & Development Council of New Jersey ,2011-11-11 08:16:00-05:00,IMMU,positive
662896.0,"Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint  ",2011-11-08 06:42:00-05:00,IMMU,positive
662897.0,Immunomedics Announces FDA Allows Resumption of Clivatuzumab Tetraxetan Clinical Trial,2011-11-02 11:17:00-04:00,IMMU,neutral
662898.0,"End-of-Day Market Summary for October 11, 2011 ",2011-10-11 16:16:00-04:00,IMMU,neutral
662899.0,Immunomedics Awarded U.S. Patent for Cytokine-Antibody Complexes  ,2011-10-11 12:56:00-04:00,IMMU,positive
662900.0,Oppenheimer Outperform on Immunomedics ,2011-09-23 08:06:00-04:00,IMMU,neutral
662901.0,Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical Trial,2011-09-22 16:16:00-04:00,IMMU,neutral
662902.0,Immunomedics  Reports Q4 Prelim EPS $0.03 vs $(0.06) Est; Revenues $11.1M vs $3.43M Est,2011-08-24 08:34:00-04:00,IMMU,neutral
662903.0,Immunomedics Receives Third Milestone Payment From Nycomed of $10M,2011-06-27 10:07:00-04:00,IMMU,neutral
662904.0,Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography  ,2011-06-08 16:39:00-04:00,IMMU,neutral
662905.0,Immunomedics Announces Antibody-Directed Radiation Therapy Appears to Improve Response to Standard-of-Care for Aggressive Lymphoma  ,2011-06-07 16:32:00-04:00,IMMU,positive
662906.0,Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan and Low-Dose Gemcitabine in Advanced Pancreatic Cancer  ,2011-06-07 11:35:00-04:00,IMMU,negative
662907.0,Immunomedics Reports First Clinical Results of New Antibody-Directed Radiation Therapy for Colorectal Cancer  ,2011-06-06 12:30:00-04:00,IMMU,negative
662908.0,Immunomedics Reports Q3 EPS of $(0.10) vs $(0.08) Estimate (IMMU),2011-05-10 08:36:00-04:00,IMMU,neutral
662909.0,Immunomedics Announces Results From Single-Dose Escalation Study of Y-90-Clivatuzumab Tetraxetan in Advanced Pancreatic Cancer Published  ,2011-05-02 10:29:00-04:00,IMMU,negative
662910.0,Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share,2011-04-06 09:54:00-04:00,IMMU,positive
662911.0,Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share,2011-04-06 09:54:00-04:00,IMMU,positive
662913.0,Immunomedics Reports Progress on Development of Antibody-SN-38 Conjugates at Cancer Meeting  ,2011-04-05 08:32:00-04:00,IMMU,negative
662914.0,Immunomedics Awarded Three US Patents Covering Its Cancer Therapeutic Product Candidates and Technologies  ,2011-03-24 08:43:00-04:00,IMMU,negative
662915.0,"Calls Purchased on Immunomedics, Inc. (IMMU)",2011-01-21 11:51:00-05:00,IMMU,neutral
662916.0,"Could This Company Help Steve Jobs?  (IMMU, AAPL)",2011-01-21 11:34:00-05:00,IMMU,positive
662917.0,UCB's Progress On-Track - Analyst Blog,2011-01-12 09:01:00-05:00,IMMU,positive
662918.0,UCB's Progress On-Track - Analyst Blog,2011-01-12 08:30:00-05:00,IMMU,positive
662919.0,UCB Commences Patient Enrolment - Analyst Blog,2010-12-15 12:30:00-05:00,IMMU,neutral
662920.0,UCB Commences Patient Enrolment - Analyst Blog,2010-12-15 12:00:00-05:00,IMMU,neutral
662921.0,"Zacks' Voice of the People highlights opportunities with Immunomedics, Coca-Cola Amatil, Wyndham Worldwide, Krispy Kreme and TPC Group   - Press Releases",2010-11-05 12:24:00-04:00,IMMU,positive
662922.0,Is Zacks Really Any Good? - Voice of the People,2010-11-04 18:54:00-04:00,IMMU,positive
662923.0,Unconfirmed rumor that GlaxoSmithKline plc (GSK) will acquire Immunomedics Inc. (IMMU) at $12.00,2010-10-21 10:23:00-04:00,IMMU,negative
662924.0,"Early Volume Plays Among Those Valued Below $10 (HEV, SNV, SBIB, IMMU, PWER)",2010-06-16 10:19:00-04:00,IMMU,positive
662925.0,"Benzingaâs Top Pre-Market Gainers (SMTS, NBIX, IMMU, CLNE)",2010-06-16 08:40:00-04:00,IMMU,positive
662926.0,Brean Murray Carret & Co. Sees Huge Upside In Immunomedics (IMMU),2010-05-11 13:51:00-04:00,IMMU,positive
662927.0,"Benzingaâs Top Pre-Market Gainers (IMMU, POZN, ONXX, TASR, SQNM)",2010-04-19 09:06:00-04:00,IMMU,positive
662928.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,IMMU,positive
662929.0,"Benzingaâs Top Pre-Market Gainers (HD, M, IMMU, TXIC, FDML)",2010-02-23 08:51:00-05:00,IMMU,positive
662930.0,Benzinga's Intraday Sector Leaders,2010-02-17 14:19:00-05:00,IMMU,neutral
662931.0,"Immunomedics, Inc. (NASDAQ: IMMU) Climbs On News",2010-01-25 09:18:00-05:00,IMMU,neutral
662932.0,"Benzingaâs Top Pre-Market Gainers (ANDS, LOGI, IMMU, CNXT, APWR, ERIC)",2010-01-22 08:22:00-05:00,IMMU,positive
662933.0,"Benzingaâs Top Pre-Market Gainers (DDSS, IMMU, VVUS, LUNA, AA, SOLF, TUES)",2010-01-11 08:24:00-05:00,IMMU,positive
